Key result
Plasma extracellular vesicle proteins HCG1745306 and histone H1.2 identified as potential ER+ breast cancer biomarkers.
Why the study?
Extracellular vesicles are emerging as potential diagnostic targets in cancer, but their protein biomarkers for early ER+ breast cancer and lymph node involvement need investigation.
Can blood-derived extracellular vesicle proteins serve as biomarkers for the diagnosis of early ER+ breast cancer and detection of lymph node involvement?
Observational (n=11)
Yes
Can blood-derived extracellular vesicle proteins serve as biomarkers for the diagnosis of early ER+ breast cancer and detection of lymph node involvement?
Two putative plasma EV biomarkers were identified that may help detect early ER+ breast cancer and lymph node involvement, warranting further validation.
May support noninvasive EV-based detection of early ER+ breast cancer and nodal involvement; hypothesis-generating and requires prospective validation before clinical use.
Extracellular vesicles (EV’s) are membrane surrounded structures released by different cell types and are emerging as potential therapeutic and diagnostic targets in cancer. In the present study, plasma samples derived from 7 patients with metastatic and non-metastatic ER+ (estrogen receptor positive) breast cancer (BC) were collected and their respective (EVs) isolated and the protein content analyzed by mass spectrometry and FunRich analysis. Here we report on the presence of two putative plasma EV biomarkers (which were absent in healthy controls samples) that could be used to detect early ER+ breast cancer and for those with lymph node (LN) involvement However, given the preliminar nature of the work, further investigation in a larger patient cohort is warranted to corroborate these findings. If confirmed, these biomarkers could be incorporated into simple blood test kit for the early detection of those with ER+ breast cancer and lymph node involvement.
No takes yet. Share an insight, caveat, or question.
Tucker et al. (2018) conducted an observational in ER+ breast cancer (n=11). Plasma extracellular vesicle proteins (HCG1745306 isoform CRA-a and Histone H1.2) vs. Healthy controls was evaluated on Presence of specific extracellular vesicle proteins in plasma. HCG1745306 isoform CRA-a and histone H1.2 were identified as potential plasma extracellular vesicle biomarkers for early ER+ breast cancer and lymph node involvement, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: